

Heather Wakelee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12184945/publications.pdf>

Version: 2024-02-01

26
papers

3,173
citations

430874

18
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

4760
citing authors

#	ARTICLE	IF	CITATIONS
1	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERA-VOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
2	Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, . .	0.8	1
3	Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERA-VOLT Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100335.	1.1	7
4	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-III A non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 1344-1357.	13.7	689
5	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	7.0	75
6	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	16.8	6
7	TERA-VOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	16.8	51
8	COVID-19 in patients with thoracic malignancies (TERA-VOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
9	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	1.1	134
10	Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative. <i>Lung Cancer</i> , 2017, 110, 42-47.	2.0	23
11	Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. <i>Journal of Thoracic Oncology</i> , 2017, 12, 129-136.	1.1	62
12	Does plasma-based molecular testing have a role in the routine care of lung cancer?. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 599-601.	0.3	0
13	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1690-1700.	1.1	256
14	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	1.6	316
15	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	1.1	101
16	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 10-17.e1.	2.6	30
17	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016, 22, 2386-2395.	7.0	169
18	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1004-1013.	1.1	44

#	ARTICLE	IF	CITATIONS
19	Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations. <i>Clinical Lung Cancer</i> , 2015, 16, e97-e99.	2.6	3
20	Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1573-1578.	1.1	106
21	Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review. <i>Journal of Thoracic Oncology</i> , 2010, 5, 129-139.	1.1	13
22	Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1413-1421.	6.3	100
23	Lung cancer and hormone replacement therapy – Authors' reply. <i>Lancet, The</i> , 2010, 375, 118-119.	13.7	1
24	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	13.7	282
25	Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. <i>Current Treatment Options in Oncology</i> , 2007, 8, 15-27.	3.0	115
26	Optimizing First-Line Treatment Options for Patients with Advanced NSCLC. <i>Oncologist</i> , 2005, 10, 1-10.	3.7	77